Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.
Merck calls ACIP’s pneumococcal recommendation a ‘missed opportunity,’ advocates for expanding age group
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS